North East and North Cumbria
ICS Formulary
ICS Formulary
9 Nutrition and blood
09-08-01 Mucopolysaccharidosis I
| Elosulfase alfa |
|
Formulary
|
|
 NICE HST19: Elosulfase alfa for treating mucopolysaccharidosis type 4A |
|
Links
NENC Guidelines for the recognition and management of non-IgE cow’s milk protein allergy (CMA) in infants- NHSE Specialised Commissioning Policy 2577: Subcutaneous copper histidinate injections for presymptomatic neonates with classical Menkes disease
- NICE HST19: Elosulfase alfa for treating mucopolysaccharidosis type 4A
- NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia
- NICE HST25: Lumasiran for treating primary hyperoxaluria type 1
- NICE HST26: Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency
- NICE HST29: Velmanase alfa for treating alpha-mannosidosis
- NICE HST30: Sebelipase alfa for treating Wolman disease
- NICE HST32: Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type B
- NICE HST33: Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over
- NICE HST4: Migalastat for treating Fabry disease
- NICE HST5 Eliglustat for treating type 1 Gaucher disease
- NICE TA821: Avalglucosidase alfa for treating Pompe disease
- NICE TA912: Cipaglucosidase alfa with miglustat for treating late-onset Pompe disease
- NICE TA915: Pegunigalsidase alfa for treating Fabry’s disease
- NICE TA961: Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal)